Pathway Diagram

flowchart TD
    OCLN["OCLN<br/>Gene"]
    OCCLUDIN["OCCLUDIN<br/>Protein"]
    TIGHT_JUNCTION["Tight Junction<br/>Formation"]
    EPITHELIAL_BARRIER["Epithelial Barrier<br/>Integrity"]
    BARRIER_FUNCTION["Blood-Brain Barrier<br/>Function"]
    
    IL4["IL-4<br/>Cytokine"]
    IL13["IL-13<br/>Cytokine"]
    MIR193B5P["miR-193b-5p<br/>MicroRNA"]
    CMVS["CMVS<br/>Protein"]
    BENVITIMOD["Benvitimod<br/>Drug"]
    
    MS["Multiple<br/>Sclerosis"]
    ALS["Amyotrophic Lateral<br/>Sclerosis"]
    STROKE["Stroke"]
    INFLAMMATION["Neuroinflammation"]
    BLC_PMG["Band-like Calcification<br/>with Polymicrogyria"]
    NEURODEVELOPMENTAL["Neurodevelopmental<br/>Disorders"]
    
    OCLN -->|"encodes"| OCCLUDIN
    OCLN -->|"participates_in"| TIGHT_JUNCTION
    OCCLUDIN -->|"maintains"| EPITHELIAL_BARRIER
    TIGHT_JUNCTION -->|"maintains"| BARRIER_FUNCTION
    EPITHELIAL_BARRIER -->|"protects"| BARRIER_FUNCTION
    
    IL4 -->|"inhibits"| OCLN
    IL13 -->|"inhibits"| OCLN
    MIR193B5P -->|"inhibits"| OCLN
    CMVS -->|"activates"| OCLN
    BENVITIMOD -->|"activates"| OCLN
    
    OCLN -->|"dysfunction_causes"| MS
    OCLN -->|"dysfunction_causes"| ALS
    OCLN -->|"dysfunction_causes"| STROKE
    OCLN -->|"dysfunction_causes"| INFLAMMATION
    OCLN -->|"mutations_cause"| BLC_PMG
    OCLN -->|"dysfunction_causes"| NEURODEVELOPMENTAL
    
    BARRIER_FUNCTION -->|"breakdown_leads_to"| INFLAMMATION
    INFLAMMATION -->|"promotes"| MS
    INFLAMMATION -->|"promotes"| ALS
    
    style OCLN fill:#006494
    style OCCLUDIN fill:#006494
    style TIGHT_JUNCTION fill:#1b5e20
    style EPITHELIAL_BARRIER fill:#1b5e20
    style BARRIER_FUNCTION fill:#1b5e20
    style IL4 fill:#ef5350
    style IL13 fill:#ef5350
    style MIR193B5P fill:#4a1a6b
    style CMVS fill:#1b5e20
    style BENVITIMOD fill:#1b5e20
    style MS fill:#5d4400
    style ALS fill:#5d4400
    style STROKE fill:#5d4400
    style INFLAMMATION fill:#ef5350
    style BLC_PMG fill:#5d4400
    style NEURODEVELOPMENTAL fill:#5d4400

OCLN — Occludin

Overview

OCLN (Occludin) is a transmembrane tight junction protein crucial for maintaining blood-brain barrier (BBB) function. It plays a key role in regulating paracellular permeability and protecting the brain from peripheral molecules [1].

Introduction

Occludin was the first identified tight junction transmembrane protein. It is a 65 kDa protein with four transmembrane domains that forms the structural basis of tight junctions. Unlike claudins, occludin is not essential for tight junction formation but is critical for maintaining barrier function and signaling [2].

Gene Structure

The OCLN gene is located on chromosome 5q13.2 and encodes a protein of 522 amino acids. The gene is expressed in endothelial and epithelial cells throughout the body, with high expression in brain microvascular endothelial cells.

Protein Structure

Occludin has a unique structure:

• Four transmembrane domains creating two extracellular loops

• N-terminal cytoplasmic domain: Interacts with the actin cytoskeleton

• C-terminal cytoplasmic tail: Binds to ZO-1 and other scaffolding proteins

• Extracellular loops: Mediate cell-cell adhesion

Normal Physiological Function

Blood-Brain Barrier

• Maintains tight junction integrity

• Regulates paracellular transport

• Controls barrier permeability

Signaling Functions

• Participates in tight junction assembly signaling

• Responds to inflammatory cytokines

• Regulates barrier remodeling

Role in Neurodegeneration

Alzheimer’s Disease

• OCLN expression is reduced in AD brains

• BBB breakdown correlates with neuropathology

• Amyloid-beta can disrupt occludin-based barriers [3]

Parkinson’s Disease

• Contributes to neuroinflammation

• May affect drug delivery to the brain

Stroke

• Acute disruption of occludin after stroke

• Target for neuroprotective therapies

• Marker of BBB damage

Multiple Sclerosis

• Downregulated in MS lesions

• Loss correlates with disease activity

Therapeutic Implications

Drug Delivery

• Understanding OCLN regulation can improve BBB targeting

• Cytokine modulation can transiently open barriers

Biomarkers

• CSF occludin levels indicate BBB damage

• Useful for monitoring disease progression

Key Publications

1. Cummins, Occludin in barrier function (2012). Trends in Cell Biology.

2. Hawkins & Davis, The blood-brain barrier in neurodegeneration (2005). Pharmacology & Therapeutics.

3. Sweeney et al., Blood-brain barrier breakdown in Alzheimer’s disease (2019). Nature Reviews Neurology.

Background

The study of Ocln — Occludin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas - Gene expression data across brain regions

• Allen Mouse Brain Atlas - Mouse brain gene expression

• Allen Cell Type Atlas - Single-cell transcriptomics data

• BrainSpan Atlas of the Developing Human Brain - Developmental transcriptome data

• Allen Brain Map Portal - Interactive data exploration

External Links

• NCBI Gene: https://www.ncbi.nlm.nih.gov/gene/4950

• UniProt: https://www.uniprot.org/uniprot/Q16625

• Ensembl: https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130940

See Also

• Blood-Brain Barrier Overview

• Neurovascular Unit CLDN5 Gene

• Alzheimer’s Disease

• Parkinson’s Disease

• Genes Index

• Proteins Index